BioCentury | Feb 22, 2018
Targets & Mechanisms

Molecular mentality

A Science study of gene expression signatures in psychiatric disease patients is the field’s largest transcriptomic readout to date, moving it closer toward molecular characterization of mental disorders. By helping map targets and pathways, the...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
BioCentury | Feb 1, 2016
Finance

Emerging in Denmark

After three years of testing the waters, the board of Lundbeck Foundation wants to ramp up its early stage investing. The group has tasked its Lundbeckfond Emerge unit with investing about €40 million ($40.4 million)...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
BioCentury | Feb 2, 2009
Company News

Lundbeck, LifeCycle Pharma, Lundbeck Foundation deal

Lundbeck sold its 27.1% stake in drug delivery company LifeCycle to the foundation's LFI A/S holding company for DKK18 per share, or about DKK275.6 million ($47.9 million). The price is a 49% premium to LifeCycle's...
BioCentury | Nov 19, 2007
Strategy

Reloading in a hurry

H. Lundbeck A/S has had a trying year, with the loss of two major late-stage CNS programs that had been expected to compensate for the loss of revenues when its top-selling CNS drugs go off...
Items per page:
1 - 6 of 6
BioCentury | Feb 22, 2018
Targets & Mechanisms

Molecular mentality

A Science study of gene expression signatures in psychiatric disease patients is the field’s largest transcriptomic readout to date, moving it closer toward molecular characterization of mental disorders. By helping map targets and pathways, the...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
BioCentury | Feb 1, 2016
Finance

Emerging in Denmark

After three years of testing the waters, the board of Lundbeck Foundation wants to ramp up its early stage investing. The group has tasked its Lundbeckfond Emerge unit with investing about €40 million ($40.4 million)...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
BioCentury | Feb 2, 2009
Company News

Lundbeck, LifeCycle Pharma, Lundbeck Foundation deal

Lundbeck sold its 27.1% stake in drug delivery company LifeCycle to the foundation's LFI A/S holding company for DKK18 per share, or about DKK275.6 million ($47.9 million). The price is a 49% premium to LifeCycle's...
BioCentury | Nov 19, 2007
Strategy

Reloading in a hurry

H. Lundbeck A/S has had a trying year, with the loss of two major late-stage CNS programs that had been expected to compensate for the loss of revenues when its top-selling CNS drugs go off...
Items per page:
1 - 6 of 6